Medical Device News Magazine

Northwell Cancer Institute Appoints Dr Douglas Gladstone Chief of Hematologic Malignancies

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Northwell Health announced today it has appointed Dr Douglas Gladstone a leader in hematology and medical oncology, as chief of hematologic malignancies at the Northwell Health Cancer Institute.

Prior to joining Northwell, Dr. Gladstone served for 14 years as clinical director of the outpatient bone marrow transplantation program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD.

In his new role, Dr. Gladstone will work with physician leaders in leukemia, lymphoma, multiple myeloma, bone marrow transplant and classic hematology to enhance clinical and research programs.

“We are thrilled Dr. Gladstone has joined Northwell’s Cancer Institute to lead the division of hematologic malignancies across our health system in the New York metropolitan region,” said Richard Barakat, MD, physician-in-chief and director of the Northwell Health Cancer Institute, and senior vice president of cancer services at Northwell Health. “His more than two decades of clinical expertise, cutting-edge research and academic teaching in the field of blood cancers and benign blood disorders will be a tremendous asset at the Cancer Institute as we advance programs and drive innovative approaches for cancer treatments.”

At the Cancer Institute, Dr. Gladstone will help establish an outpatient hematopoietic and cellular transplant center at Northwell, broaden the use of CAR T-cell therapy, and explore the role of transplanting regulatory T cells, which modulate our immune response and have the potential to treat chronic inflammatory diseases and severe infections such as COVID-19.

“Among my key goals will be to collaborate with my colleagues to unify hematology care across the health system as well as help lead efforts for the Northwell Cancer Institute to earn National Cancer Institute (NCI)-designation, which recognizes cancer centers for their scientific leadership in laboratory and clinical research, as well as serving their communities and promoting and training a range of healthcare professionals”

Dr. Gladstone received his medical degree at the NYU Grossman School of Medicine, completed his residency and chief residency at the University of Rochester, followed by dual fellowships in hematology and medical oncology at the Johns Hopkins University School of Medicine. After completing his fellowships, Dr. Gladstone became further involved in clinical research, immunotherapy and in blood and bone marrow transplantation research. He is an associate professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

In addition, Dr. Gladstone will partner with Cancer Institute leadership to further advance faculty engagement in clinical research recruitment and catalyze new clinical and translational research initiatives. He will work collaboratively with leadership to improve process and flow within the outpatient R.J. Zuckerberg Cancer Center to support efficiencies, programmatic growth and oversee the future transfer of the bone marrow transplant and leukemia units from North Shore University Hospital in Manhasset to the R.J. Zuckerberg Cancer Hospital at Long Island Jewish Medical Center in New Hyde Park.

With more than 400 physicians, Northwell Health Cancer Institute treats more than 19,000 cancer patients annually, more than any other provider in New York State.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”